TY - JOUR
T1 - Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients
AU - Lim, Emerson A.
AU - Gunther, Jacqueline E.
AU - Kim, Hyun K.
AU - Flexman, Molly
AU - Hibshoosh, Hanina
AU - Crew, Katherine
AU - Taback, Bret
AU - Campbell, Jessica
AU - Kalinsky, Kevin
AU - Hielscher, Andreas
AU - Hershman, Dawn L.
N1 - Funding Information:
This study was funded by Grants from the Komen Foundation for the Cure Post Doctoral Fellowship Research Grant to EAL, National Science Foundation Integrative Graduate Education and Research Traineeship program on Optical Techniques for Actuation, Sensing, and Imaging of Biological Systems at Columbia University to JEG, and the Natural Sciences and Engineering Research Council of Canada (NSERC) to MF. This publication was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant No. KL2 TR000081 to KK. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This research was also supported in part by the Witten Family Fund.
Publisher Copyright:
© 2017, Springer Science+Business Media New York.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Purpose: Breast cancer (BC) patients who achieve a favorable residual cancer burden (RCB) after neoadjuvant chemotherapy (NACT) have an improved recurrence-free survival. Those who have an unfavorable RCB will have gone through months of ineffective chemotherapy. No ideal method exists to predict a favorable RCB early during NACT. Diffuse optical tomography (DOT) is a novel imaging modality that uses near-infrared light to assess hemoglobin concentrations within breast tumors. We hypothesized that the 2-week percent change in DOT-measured hemoglobin concentrations would associate with RCB. Methods: We conducted an observational study of 40 women with stage II–IIIC BC who received standard NACT. DOT imaging was performed at baseline and 2 weeks after treatment initiation. We evaluated the associations between the RCB index (continuous measure), class (categorical 0, I, II, III), and response (RCB class 0/I = favorable, RCB class II/III = unfavorable) with changes in DOT-measured hemoglobin concentrations. Results: The RCB index correlated significantly with the 2-week percent change in oxyhemoglobin [HbO2] (r = 0.5, p = 0.003), deoxyhemoglobin [Hb] (r = 0.37, p = 0.03), and total hemoglobin concentrations [HbT] (r = 0.5, p = 0.003). The RCB class and response significantly associated with the 2-week percent change in [HbO2] (p ≤ 0.01) and [HbT] (p ≤ 0.02). [HbT] 2-week percent change had sensitivity, specificity, positive, and negative predictive values for a favorable RCB response of 86.7, 68.4, 68.4, and 86.7%, respectively. Conclusion: The 2-week percent change in DOT-measured hemoglobin concentrations was associated with the RCB index, class, and response. DOT may help guide NACT for women with BC.
AB - Purpose: Breast cancer (BC) patients who achieve a favorable residual cancer burden (RCB) after neoadjuvant chemotherapy (NACT) have an improved recurrence-free survival. Those who have an unfavorable RCB will have gone through months of ineffective chemotherapy. No ideal method exists to predict a favorable RCB early during NACT. Diffuse optical tomography (DOT) is a novel imaging modality that uses near-infrared light to assess hemoglobin concentrations within breast tumors. We hypothesized that the 2-week percent change in DOT-measured hemoglobin concentrations would associate with RCB. Methods: We conducted an observational study of 40 women with stage II–IIIC BC who received standard NACT. DOT imaging was performed at baseline and 2 weeks after treatment initiation. We evaluated the associations between the RCB index (continuous measure), class (categorical 0, I, II, III), and response (RCB class 0/I = favorable, RCB class II/III = unfavorable) with changes in DOT-measured hemoglobin concentrations. Results: The RCB index correlated significantly with the 2-week percent change in oxyhemoglobin [HbO2] (r = 0.5, p = 0.003), deoxyhemoglobin [Hb] (r = 0.37, p = 0.03), and total hemoglobin concentrations [HbT] (r = 0.5, p = 0.003). The RCB class and response significantly associated with the 2-week percent change in [HbO2] (p ≤ 0.01) and [HbT] (p ≤ 0.02). [HbT] 2-week percent change had sensitivity, specificity, positive, and negative predictive values for a favorable RCB response of 86.7, 68.4, 68.4, and 86.7%, respectively. Conclusion: The 2-week percent change in DOT-measured hemoglobin concentrations was associated with the RCB index, class, and response. DOT may help guide NACT for women with BC.
KW - Breast cancer
KW - Diffuse optical tomography
KW - Imaging
KW - Neoadjuvant chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=85012236204&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012236204&partnerID=8YFLogxK
U2 - 10.1007/s10549-017-4150-7
DO - 10.1007/s10549-017-4150-7
M3 - Article
C2 - 28190249
AN - SCOPUS:85012236204
SN - 0167-6806
VL - 162
SP - 533
EP - 540
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 3
ER -